Icotrokinra dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Icotrokinra is a small peptide of 13 amino acids, taken as a pill, that blocks the IL-23 receptor. It is the first pill to hit that pathway, in a class that used to be shots only.
Evidence grade for Icotrokinra: Moderate. The rule: at least one finished study in people, and at least 100 people who took it. The sum on this page: 2 completed trials, 311 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 311
- Human studies
- 2
- Found nothing
- 0
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
FDA approved 2026 for moderate to severe plaque psoriasis. Prescription only.
3 effects reported, 2 unwanted, 1 wanted, by people using it, not a trial
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Icotrokinra is a daily pill for plaque psoriasis. It is a small peptide that blocks the IL-23 receptor, a switch that drives psoriasis. Before it, drugs for this switch were all shots. It was approved in the US in 2026.
What people take it for
- Clearing psoriasis without shots.
- Treating psoriasis on the scalp, genitals, hands and feet.
What studies in people showed
The main study had 311 people aged 12 and over. They took the pill or a dummy pill. After 16 weeks, the dummy group moved onto the drug. From 6 months to a year, 67 to 70 percent had clear or almost clear skin. The scalp did better, at 72 to 78 percent. Genital skin did best, at 85 to 90 percent. Hands and feet lagged, at 54 to 62 percent. 88 percent stayed on it the full year. In the first 16 weeks, side effects were about as common as on the dummy pill.
What people report
Reports, not study results
The good
- In the studies on this page, most people had clear or almost clear skin, and it held for a year.
The bad
- Hands and feet cleared less well than other spots in the study on this page.
- A year of data cannot show rare or slow harms.
Where these come from: All of it is from the studies on this page. We have not collected forum or user reports for this drug yet.
My bottom line
If you have psoriasis, this is worth a talk with your skin doctor. A pill is easier than a shot. Ask how it compares with the shots for your skin.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Nothing indexed yet
The 3 citations on this page do not report a result for any of the 36 goals indexed here. Most of what sits here is something else: a listing of a planned study, a study of how the body handles the drug, a safety report or a government record. None of those tests whether it works.
Show full evidence
What is Icotrokinra?
Icotrokinra is a small peptide of 13 amino acids, taken as a pill, that blocks the IL-23 receptor. It is the first pill to hit that pathway, in a class that used to be shots only.
IL-23 is an immune signal that drives plaque psoriasis. The drugs that block it work very well, but all of them were antibody shots. Icotrokinra is a peptide of 13 amino acids that locks tightly onto the IL-23 receptor and is taken by mouth. That makes it the first pill aimed at this pathway. It was approved in 2026 for plaque psoriasis. In a study of 311 people aged 12 and over, about 67 to 70 percent had clear or almost clear skin from 6 months to a year. The scalp did better, at 72 to 78 percent, and genital skin better still, at 85 to 90 percent. Hands and feet lagged, at 54 to 62 percent. It is on this site as a milestone for peptide pills, not because most readers are likely to take it.
How does Icotrokinra work?
It locks onto the IL-23 receptor very tightly and blocks the IL-23 signal. The older IL-23 drugs are antibodies that grab the signal itself. This one blocks the receptor instead, and its small size is what lets it work as a pill.
What have studies in people found about Icotrokinra?
Strong, and unusually complete for a newly approved drug. There are several large final-stage studies, a year of data on how long the effect lasts, and a comparison against the shots.
- ICONIC-TOTAL: 311 people, including teens from age 12, took the pill or a dummy pill. The dummy group switched to the drug at week 16.
- Between weeks 24 and 52, 67 to 70 percent of treated people had clear or almost clear skin overall.
- Genital psoriasis did best, at 85 to 90 percent clear or almost clear, and the scalp at 72 to 78 percent.
- Hands and feet did least well, at 54 to 62 percent. That is worth knowing if that is where your psoriasis is.
- 88 percent of people stayed on it for the full 52 weeks.
What this does not tell you: Psoriasis scores are judged by doctors and are partly a matter of opinion, though they are the standard in this field. The maker paid for the studies. And for most patients, the real question is not the pill against a dummy pill. It is the pill against the antibody shots, which work very well. Read the published comparison with those before deciding the pill is simply better.
The state of the research
A psoriasis drug is on a longevity and peptide site because of how it is taken. A peptide of 13 amino acids, taken as a daily pill, clears skin in the same range as antibody shots. That shows the peptide pill problem can be solved, at least for some targets.
Read it next to enlicitide, which does the same thing for cholesterol with a much bigger molecule. Together they are the clearest sign yet that the idea that peptides must be shots is starting to crack.
The evidence, in charts
Fig. 1a · how many people
311people, across 1 study in people cited here
| Study | People | Share |
|---|---|---|
| Journal of the European Academy of Dermatology and Venereology 2026 | 311 | 100% |
The whole total is one study of 311. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. 1 more study in people gives no headcount and is not counted here. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
2 of 3 sources here are studies in people. The rest is not.
- Study in people · done in people267%
- Review of studies · sums up other studies133%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Every source here was published in 2026.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Approved
UK
Prescription
AU
Prescription
CA
Prescription
Approved in 1 of 4, by prescription in 3, not approved in 0. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 5 · what the molecule is
- Kind of compound
- Peptide
- Molecule weight
- 13 amino acid peptide
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
No amino acid sequence is on file for Icotrokinra, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2026Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings
A daily pill cleared psoriasis in the places that are hardest to treat, and it held for a year. 311 people aged 12 and over took icotrokinra or a dummy pill. The dummy group moved onto the drug after 16 weeks. Between 6 and 12 months, around seven in ten had clear or nearly clear skin overall, and more than eight in ten had clear genital skin. Hands and feet lagged behind at around six in ten. 88 percent stayed to the end.
311 participants aged 12 and over randomised 2:1 to icotrokinra 200 mg daily or placebo, with placebo crossing over at week 16. At weeks 24 to 52, clear or almost clear overall skin in 67 to 70 percent, scalp 72 to 78 percent, genital 85 to 90 percent. Hand and foot psoriasis lagged the other sites at 54 to 62 percent. 88 percent completed 52 weeks.
- Study in people2026Safety of icotrokinra through 1 year for the treatment of moderate-to-severe plaque psoriasis
Over a year of use, side effects looked no worse than on a dummy tablet. This is the safety report rather than a test of whether the drug works. Through the first 16 weeks, while a dummy group still existed to compare against, unwanted effects happened at much the same rate on both. After that point everyone was on the drug, so there was nothing left to compare against. A year is not long enough to find rare or slow harms.
One year safety reporting. Adverse event rates through week 16 were similar between icotrokinra and placebo.
- Review of studies2026The efficacy of oral icotrokinra versus injectable IL-23 inhibitors for moderate-to-severe plaque psoriasis
This paper compares the pill with the antibody shots in the same class. That is the comparison that decides whether switching to a pill is worth it.
Comparison against the injected antibodies in the same class, which is the question that decides whether an oral option is worth switching to.
Where to buy Icotrokinra
Icotrokinra is an approved medicine. The approved product comes from a pharmacy, with a prescription. The vials below are sold “for research” and are not the approved drug.
No seller we track lists Icotrokinra yet. We read sellers’ public product lists every week, and this section fills in as soon as one does. Every seller, graded
Common questions
Has Icotrokinra been tested in people?
Yes. 311 people given it across 2 completed trials cited here, 0 of which found nothing. Icotrokinra is a small peptide of 13 amino acids, taken as a pill, that blocks the IL-23 receptor. It is the first pill to hit that pathway, in a class that used to be shots only.
What is the Icotrokinra dosage?
Approved medicine. No human dose established for unlabelled uses. Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose. FDA approved 2026 for moderate to severe plaque psoriasis. Prescription only.
Is Icotrokinra FDA-approved?
FDA approved 2026 for moderate to severe plaque psoriasis. Prescription only.
Why is a psoriasis drug on this site?
Because of how it is taken, not what it treats. It is a peptide of 13 amino acids that works as a daily pill, against a target that used to need antibody shots. That is a milestone for peptide pills in general.
How well does it work?
Through one year, 67 to 70 percent of treated people had clear or almost clear skin. Genital and scalp psoriasis did better than that. Hand and foot psoriasis did least well, at 54 to 62 percent.
Is it as good as the injections?
That comparison has been published, and it is the one that matters if you are choosing between them. The IL-23 antibody shots work very well, so a pill competes on ease as much as on results.